Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CFHR2 Biologics Sequence Review Report 2026: Complement factor H-related protein 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CFHR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CFHR1 Biologics Sequence Review Report 2026: Complement factor H-related protein 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CFHR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM8 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM8 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CENPB Biologics Sequence Review Report 2026: Major centromere autoantigen B Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CENPB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM3 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM21 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM21 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM21 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM7 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM7 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM4 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM19 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM19 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM20 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM20 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM16 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM16 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CEACAM18 Biologics Sequence Review Report 2026: Cell adhesion molecule CEACAM18 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CEACAM18 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
100
101
102
103
104
>>
1670
>